Table 2 List of grade ≥ 3 adverse events on treatment

From: The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal adenocarcinoma

Grade ≥ 3 AE (>5% frequency)

Gem+Nab-P+Durva+Treme

(n = 119)

Gem+Nab-P

(n = 58)

Any grade ≥3 AE

100 (84)

44 (76)

Fatigue

24 (20)

12 (21)

Thromboembolic event

16 (15)

7 (12)

Sepsis

13 (11)

7 (12)

Peripheral sensory neuropathy

13 (11)

7 (12)

Diarrhea

6 (5)

6 (10)

Abdominal pain

6 (5)

6 (10)

Febrile neutropenia

7 (6)

4 (7)

Vomiting

7 (6)

2 (3)

Edema limbs

5 (4)

3 (5)

Bile duct stenosis

7 (6)

0 (0)

Biliary tract infections

11 (9)

3 (5)

Lung infection

6 (5)

4 (7)

Generalized muscle weakness

1 (1)

5 (9)

Renal calculi

2 (2)

3 (5)

Dyspnea

8 (7)

4 (7)

Rash maculo-papular

7 (6)

2 (3)

Hypertension

3 (3)

4 (7)

  1. Adverse events occurring in at least 5% of either study arm are listed. AE adverse event, Gem+Nab-P+Durva+Treme Gemcitabine, nab-paclitaxel, durvalumab and tremelimumab, Gem+Nab-P, gemcitabine and nab-paclitaxel.